Reading ACON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACON free→Reading ACON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACON free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been fairly steady, and it has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, which may impact ACON's performance compared to sector peers, where it is typical. Peer multiples imply a price about 495% below where it trades (it looks expensive on this basis); the read is rich. If sector bellwethers like VEEV, BTSG, and TEM keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting ACON and other Healthcare names. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $3.03. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.03, ACON's earnings are too small for P/E to mean much; on sales it trades at 10× p/s (5.9× the 2× p/s peer median). At a normal multiple the price implies ~495% near-term growth vs our ~26% forecast. That gap is an optionality premium a financial-multiple model can't price — our $0.52 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 495% near-term growth, well above our forecast of about 26%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.91x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.95 → $-1.05 (-10.5% / 30d). 0 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$217.
How much price usually moves either way.
On a bad day, this stock has moved -$831.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,564.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ACON yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events . On April 21, 2026, the board of directors of Aclarion, Inc. (the “Company”) authorized and approved a share repurchase program. Under the share repurchase program, the Company may repurchase up to $2.5 million in value of the Company’s outstanding shares of common stock from time to time over the next 12 months. The Company may buy back its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, pu…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ACON ACLARION INC | Typical Show detailsSector percentile: 55 of 100 | expensive | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Aclarion has entered into a Material Definitive Agreement as part of its M&A strategy.
Aclarion aims to improve its operating income, which has been negative in recent quarters.
Entry into a Material Definitive Agreement. The information set forth in
Material Modification to Rights of Security Holders. On March 19, 2026, the board of directors (the “ Board ”) of Aclarion, Inc., a Delaware corporation (the “ Company ”), adopted a stockholder rights agreement and declared (i) a dividend of one right (a “ Right ”) for each outstanding share of Company common stock, par value $0.00001 per share (“ Common Stock ”), to stockholders of record at the close of business on March 30, 2026 (the “ Record Date ”) and (ii) a dividend of the aggregate nu…
Entry into a Material Definitive Agreement. On January 8, 2026, Aclarion, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with the purchasers named therein. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, in a registered direct offering (the “ Offering ”), an aggregate of (i) 200,000 shares (the “ Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”), at a price per share of $5.18 (or pre-fu…
Entry into a Material Definitive Agreement. On October 13, 2025, Aclarion, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with the purchasers named therein. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, in a registered direct offering (the “ Offering ”), an aggregate of (i) 64,000 shares (the “ Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”), at a price per share of $8.36; and (ii)…